UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 10, 2010
ALSERES PHARMACEUTICALS, INC.
 
(Exact Name of Registrant as Specified in Charter)
         
Delaware   0-6533   87-0277826
         
(State or Other Juris-
diction of Incorporation 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
     
239 South Street, Hopkinton, Massachusetts   01748
     
(Address of Principal Executive Offices)   (Zip Code)
Registrant’s telephone number, including area code: (508) 497-2360
 
(Former Name or Former Address, if Changed Since Last Report)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 1.01.   Entry into Material Definitive Agreements.
     On September 10, 2010, Alseres Pharmaceuticals, Inc. (the “Company”), entered into a Note Purchase Agreement (the “Agreement”) with Highbridge International LLC (the “Seller”) and Robert Gipson Pursuant to which the Company agreed to purchase from the Seller, effective on September 14, 2010, a Convertible Promissory Note issued on May 2, 2007 to the Seller in the principal amount of $5,880,000 for an aggregate purchase price equal to $602,700 payable in immediately available federal funds by the Company to the Seller. In a related transaction, on September 13, 2010 the Company issued to Robert L. Gipson (the “Holder”) an unsecured promissory note, pursuant to which the Company borrowed an aggregate principal amount of $700,000 (the Note”). Interest on the Note shall accrue at the rate of 7% per annum and all principal and accrued interest shall be due and payable on demand of the Holder.
     The foregoing description of the Agreement and the Note are qualified in their entirety by the full text of the Agreement and the Note, complete copies of each are filed herewith as Exhibits 10.7 and 10.8 respectively and each is incorporated herein by reference.
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Alseres Pharmaceuticals, Inc.
  		 
Date: September 16, 2010  By:   /s/ Kenneth L. Rice, Jr.    
    Kenneth L. Rice, Jr.   
    Executive Vice President, Finance and Administration and Chief Financial Officer   
 

-2-

 

EXHIBIT INDEX
         
Exhibit No.   Description
  10.7    
Note Purchase Agreement
  10.8    
Promissory Note dated September 13, 2010

-3-

Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025 Haga Click aquí para más Gráficas Alseres Pharmaceuticals (CE).
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025 Haga Click aquí para más Gráficas Alseres Pharmaceuticals (CE).